Jim Cramer Says Amgen (AMGN)'s New Drug Has Good Data

We recently published 8 Stocks Jim Cramer Discussed & Mentioned An Important Quantum Computing Development. Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer discussed.

Cramer has recently started to discuss pharmaceutical giant Amgen Inc. (NASDAQ:AMGN) more frequently. Most of his discussions surround the firm’s Repatha drug that aims to reduce cholesterol and prevent adverse cardiovascular events. In a November 11th appearance, the CNBC TV host commented that Amgen Inc. (NASDAQ:AMGN), along with JNJ, could be a stock worth owning. He added that the firm might also be working on a novel approach for the weight loss drug market. In this appearance, he commented that money was finally flowing into healthcare stocks such as Amgen Inc. (NASDAQ:AMGN):

“If you take a look at a stock like Amgen, Rob Bradway, the CEO, they’ve got a new, really good data about lowering cholesterol, much lower with Repatha and it’s going to be part of the TrumpRx. And this is what they’re going to. Now do I buy the parabolic move? No. But you need to realize that the money staying in the market, it’s just going to places it hasn’t been to in a long time.”

While we acknowledge the potential of AMGN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.